NCT02550743View on ClinicalTrials.gov

BrUOG 302:BYL719, Capecitabine and Radiation for Rectal Cancer: A Brown University Oncology Research Group Study

PHASE1TerminatedINTERVENTIONAL

Enrollment

7

Participants

Timeline

Start Date

June 3, 2016

Primary Completion Date

November 16, 2018

Study Completion Date

November 16, 2018

Conditions

Rectal Cancer

Interventions

DRUG

BYL719

DRUG

Capecitabine

RADIATION

Radiation

Trial Locations (1)

02903

Rhode Island Hospital and The Miriam Hospital, Providence

Sponsors

Collaborators (1)

Brown University

All Listed Sponsors

collaborator

Brown University

OTHER

collaborator

Lifespan

OTHER

collaborator

Novartis Pharmaceuticals Corporation (Financial supporter)

UNKNOWN

lead

howard safran

OTHER